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Abstract
G protein coupled receptor 55 (GPR55) was initially identified as the orphan receptor 
and then suggested to be the atypical “non-CB1/non-CB2” cannabinoid receptor. How-
ever, later studies revealed that GPR55 is specific for lysophosphatidylinositol (LPI) 
synthesized from membrane phosphoinositides by phospholipases A1 or A2. Recent 
findings suggest that LPI-GPR55 signaling is involved in the pathogenesis of cardio-
metabolic disorders. GPR55 is expressed in adipose tissue, endothelial cells, inflamma-
tory cells, and cardiomyocytes. Plasma LPI concentration and GPR55 expression in the 
adipose tissue are modified by nutritional status, leptin level and glucose tolerance. 
Ligand-activated GPR55 has anabolic effect in human adipose tissue, stimulates insulin 
secretion, induces hyperpolarization of endothelial cells, inhibits platelet aggregation, 
and increases Ca2+ concentration in cultured cardiomyocytes. In this review the recent 
findings about role of GPR55 signaling in adipose tissue, metabolic homeostasis and 
cardiovascular system are summarized.
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GPr55 and related receptors
G protein-coupled receptor 55 (GPR55) 
was cloned in 1999 as an orphan 
7-transmembrane domain receptor 
(1). It is encoded by the gene localized 
in humans on chromosome 2q37 and 
consists of 319 aminoacids. Its ami-
noacid sequence exhibits significant 
sequence homology with cannabinoid 
and lysophosphatidic acid G protein-
coupled receptors (Table 1). GPR55 
is abundantly expressed in the cen-
tral nervous system as well as in some 
peripheral tissues including adrenals, 
jejunum, ileum, spleen, lung, liver, 
uterus, urinary bladder, stomach and 
kidney. Human GPR55 shares 78% 
aminoacid sequence identity with the 
rodent receptor.
Because in some systems GPR55 
is activated by plant cannabinoids 
including ∆9-tetrahydrocannabinol, 
abnormal cannabidiol (abn-CBD) 
and its synthetic derivative, O-1602, 
as well as by compounds structurally 
related to endogenous cannabinoid 
anandamide (palmitoyl ethanolamine 
and oleoyl ethanolamine), it was ini-
tially suggested to be the atypical can-
nabinoid receptor (2). Indeed, some 
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effects of endogenous and exogenous cannabinoids are not me-
diated by classic CB1 and CB2 receptors, and at least one addi-
tional “non-CB1 non-CB2” cannabinoid receptor was suggested 
to exist. In addition, aminoacid sequence of GPR55 shares 13-
14% homology with CB1 and CB2 receptors (Table 1). However, 
stimulation of GPR55 by cannabinoids was observed mainly in 
cultured cells transfected with GPR55. During accumulation of 
data obtained in different cells it became evident that high affin-
ity of GPR55 to cannabinoids is observed only in some experi-
mental systems (3). Structurally, GPR55 lacks the characteristic 
cannabinoid-binding pocket present in CB receptors (4). Inter-
estingly, CB1 receptor antagonists rimonabant and its derivative, 
AM251, are agonists of GPR55, whereas synthetic CB1 receptor 
agonist, CP55940, is the antagonist of GPR55 (5). These data led 
to suggestions that GPR55 and CB1 receptors may play opposite 
roles in some systems.
In 2007 it was first recognized that GPR55 is specifically acti-
vated by lysophosphatidylinositol (LPI) (6). LPI containing fatty 
acid residue (especially arachidonic acid) at the sn-2 position of 
glycerol has higher affinity for GPR55 (EC50 about 30 nM) than 
LPI with fatty acid at the sn-1 position (EC50 about 4500 nM) (7). 
However, concentrations of these LPI species in tissues are much 
higher, about 10 μM and 25 μM, respectively, so both 1-acyl- 
and 2-acyl-LPI may be relevant GPR55 agonists in vivo (8). 
The related lysophospholipid lacking the inositol moiety, that is 
2-acyl-glycerol 3-phosphate (2-acyl lysophosphatidic acid), acti-














LPAR4 (GPR23) 30% 1-acyl-glycerol 3-phosphate (1-acyl-LPA)
LPAR6 (P2y5) 29% 2-acyl-glycerol 3-phosphate (2-acyl-LPA)









Abn-CBD – abnormal cannabidiol
LPA – lysophosphatidic acid
LPAR – lysophosphatidic acid receptor
2-AG – 2-arachidonyl-gltcerol
AEA – arachidonyl-ethanolamine (anandamide).
*potent agonist for rat but weak for human receptor 
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vates lysophosphatidic acid (LPA) receptors LPAR3 and LPAR6, 
as well as GPR35 receptor which, in rats but not in humans, also 
binds with high affinity the endogenous tryptophan metabolite, 
kynurenic acid (9,10). The remaining LPA receptors (LPAR1, 2, 
4 and 5) bind 1-acyl-LPA and 2-acyl-LPA with similar affinities 
or show the preference for the former compound. Thus, GPR55 
can be classified as the member of superfamily of lysophospho-
lipid and cannabinoid receptors, although it is the only known 
LPI receptor. The other “orphan” receptor, GPR34, is activated 
by a related species, 2-acyl-glycerol 3-phosphoserine (2-acyl 
lysophosphatidylserine) (11).
synthesis and metabolism of lPi
Phosphatidylinositol (1,2-diacyl-glycerol 3-phosphoinositol) is 
one of plasma membrane phospholipids and is especially abun-
dant in the brain where it may constitute 10% of all phospho-
lipids (8). The most abundant fatty acids in phosphoinositides 
are stearic acid (18:0) at the sn-1 position and arachidonic acid 
(20:4) at the sn-2 position. Synthesis of phosphatidylinositol is 
initiated by esterification of the 1st and the 2nd carbon of glycerol 
3-phosphate by acyl-CoA: glycerol-3-phosphate acyltransferase 
(GPAT) and acyl-CoA:1-acyl-glycerol-3-phosphate acyltrans-
ferase (AGPAT) to form phosphatidic acid (Fig. 1). Then, phos-
phatidylinositol is synthesized by sequential action of CDP-dia-
cylglycerol synthase and phosphatidylinositol synthase. 1-Acyl-
LPI (1-acyl-glycerol 3-phosphoinositol) and 2-acyl-LPI (2-acyl-
glycerol 3-phosphoinositol) are formed from phosphatidylinosi-
tol by phospholipases A2 and A1, respectively (Fig. 1). The most 
abundant LPI species are 1-stearoyl-sn-glycerol 3-phosphoino-
sitol (1-SGPI) and 2-arachidonyl- sn-glycerol 3-phosphoinosi-
Figure 1. synthesis and metabolism of lysophosphatidylinositol (LPI) and lysophospholipid agonists of the related G protein-
coupled receptors. GPAT – glycerol 3-phosphate acyltransferase, AGPAT – 1-acyl-glycrol 3-phosphate acyltransferase, CDP – citi-
dine diphosphate, DAG – diacylglycerol, PI – phosphatidylinositol, PLA1 – phospholipase A1, PLA2 – phospholipase A2, LPI-PLA1 
– Lysophosphatidylinositol-specific phospholipase A1, PLC – phospholipase C, PLD – phospholipase D, LPA – lysophosphatidic 
acid, LPAR – lysophosphatidic acid receptor, MAG – monoacylglycerol, 2-AG – 2-arachidonyl-glycerol, CB1, CB2 – cannabinoid 
receptors.
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tol (2-AGPI). LPI are released to the extracellular space by at 
least some cell types through the plasma membrane transporter 
ABCC1 (8). Both 1-acyl- and 2-acyl-glycerol 3-phosphoinosi-
tols activate GPR55, although 2-AGPI was demonstrated to be 
the most potent agonist among different LPI species (7). LPIs 
are back converted to phosphatidylinositol by acyl-CoA:LPI 
acyltransferases (LPIAT). Alternatively, 1-acyl-glycerol 3-phos-
phoinositols are substrates for lysophospholipase A1 (LPI-PLA1) 
which releases the sn-1 linked fatty acid thus forming glycerol 
3-phosphoinositol. In addition, both 1-acyl- and 2-acyl-glycerol 
3-phosphoinositols may be hydrolyzed by LPI-specific phos-
pholipase C (LPI-PLC) to inositol phosphate and respective 
1- or 2-monoacylglycerol, respectively, or by lysophospholipase 
D to inositol and 1-acyl- or 2-acyllysophosphatidic acid (8). 
The significance of these enzymatic reactions in the regulation 
of LPI level and GPR55 signaling is unclear, especially in pe-
ripheral tissues. Some of these products activate the related G 
protein-coupled receptors. 2-arachidonyl-glycerol is the specific 
cannabinoid CB1 and CB2 receptor agonist, whereas 2-acyl-ly-
sophosphatidic acid activates GPR35, LPAR3 and LPAR6 (Fig. 
1). In addition, 2-arachidonyl-LPA may be dephosphorylated to 
2-arachidonyl-glycerol by LPA phosphatase and the latter may 
be again phosphorylated to 2-arachidonyl-LPA by monoacylg-
lycerol kinase. Thus, agonists of lysophospholipid and cannabi-
noid receptors may be interconverted.
GPr55 signaling mechanisms
GPR55 is coupled to heterotrimeric G protein containing ei-
ther Gα12 or Gα13 subunit (G12 subfamily of α subunits of het-
erotrimeric G proteins) (12-14). Ligand binding triggers the 
exchange of GDP for GTP and dissociation of αβγ trimer into 
Gα12/13 subunit and Gβγ dimer; Gα12/13 then activates guanine 
nucleotide exchange factor (GEF) of small monomeric Rho 
proteins. Exchange of GDP for GTP activates RhoA protein, 
which is involved in the regulation of actin polymerization, as-
sembly of focal adhesions, gene transcription, and control of 
cell growth. GPR55-activated RhoA has been demonstrated to 
stimulate Rho-dependent kinase which activates phospholipase 
C resulting in the increase in inositol 1,4,5-triphosphate (IP3) 
and release of calcium from intracellular stores (14). In addition, 
GPR55 activates nuclear factor of activated T cells (NFAT) in the 
calcineurin-dependent manner, p38 mitogen activated protein 
kinase, extracellular signal-regulated kinases (ERK), cyclic AMP 
response element-binding protein (CREBP) and nuclear factor 
κB (NF-κB) in various cell types (13). 
GPr55 in adipose tissue
Since the discovery of leptin in 1994 secretory function of adi-
pose tissue became increasingly apparent. Although this func-
tion is usually attributed to proteins referred to as adipokines, 
it should be kept in mind that adipose tissue produces also 
non-protein biologically active mediators including lipids. In 
particular, endogenous cannabinoid system is functioning in 
the adipose tissue with both endocannabinoid-synthesizing en-
zymes and cannabinoid receptors being abundantly expressed 
(15). Adipose tissue cannabinoid signaling is overactive in obe-
sity and exerts unbeneficial effects on metabolism, mitochon-
drial biogenesis, insulin sensitivity and adipokine secretion (16).
Recently, Morreno-Navarrete et al (17) reported that GPR55 
is abundantly expressed in human visceral and subcutaneous 
adipose tissue at both mRNA and protein levels. The amount 
of GPR was higher in obese than in lean patients and within 
the obese group was greater in those with type 2 diabetes or im-
paired glucose tolerance than in subjects with normal glucose 
tolerance. When visceral and subcutaneous adipose tissue sam-
ples from the same patient were compared, both GPR55 mRNA 
and protein were higher in the former. Furthermore, GPR55 
gene expression in visceral adipose tissue exhibited a signifi-
cant positive correlation with body weight, BMI, percent body 
fat and circulating LPI level in multivariate regression analysis, 
and this correlation was stronger in women than in men. No 
correlation between GPR55 expression and body composition 
measures was observed in subcutaneous adipose tissue. In con-
trast to adipose tissue, the expression of GPR55 in the liver was 
similar in lean and obese patients suggesting that up-regulation 
of GPR55 is tissue-specific. The level of GPR55 was similar in 
adipocytes and stromovascular fraction which contains endo-
thelial cells, macrophages, lymphocytes and mast cells (17).
In addition, plasma LPI concentration was higher in obese 
than in lean patients, which is true for both total LPI concen-
tration and several individual LPI species such as steraroyl-LPI, 
palmitoyl-LPI and arachidonyl-LPI. However, in contrast to 
GPR55, LPI concentration in the obese group tended to be lower 
in those with impaired glucose tolerance or type 2 diabetes than 
in normoglycemic subjects. Plasma LPI level was positively cor-
related with body weight, BMI and percent body fat in women 
but not in men, whereas there was no significant difference in 
plasma total LPI and individual LPI species between sexes (17).
Although these human studies suggest that GPR55 is up-reg-
ulated in obesity, the results obtained in experimental animals 
are less clear. For example, GPR55 expression at both mRNA 
and protein level was significantly reduced in two experimen-
tal models of obesity: leptin-deficient ob/ob mice and rats made 
obese by feeding high-fat diet (17). In a recent study (18), 24- or 
48-hour food deprivation increased GPR55 mRNA and protein 
in gonadal adipose tissue in male and female Sprague-Dawley 
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rats. This effect was reversed by re-feeding and was prevented 
by leptin administration. These data suggest that increase in 
GPR55 expression in adipose tissue is mediated by fasting-in-
duced hypoleptinemia (18). Plasma LPI (total, stearoyl-LPI, pal-
mitoyl-LPI and arachidonyl-LPI) were decreased by fasting and 
restored by leptin treatment. Similarly to acute fasting, chronic 
food deprivation associated with weight loss increased the ex-
pression of GPR55 in white adipose tissue. Interestingly, changes 
in CB1 receptor expression in white adipose tissue after short- or 
long-term food deprivation paralleled those of GPR55. 
Other conditions demonstrated to affect the LPI-GPR55 
system in adipose tissue are presented in Table 2. Although the 
regulation of this pathway in adipose tissue is far from being 
understood, several conclusions can be drawn from these data. 
First, LPI-GPR55 system is affected by nutritional and energy 
status as well as by leptin level. In rats, the expression of GPR55 
in adipose tissue seems to be inhibited by leptin because states 
associated with the increase in leptin level such as obesity or late 
pregnancy are also characterized by decrease in GPR55, and vice 
versa, conditions associated with hypoleptinemia (short-term 
fasting and weight loss) result in the up-regulation of this recep-
tor. Second, expression of GPR55 and CB1 in the adipose tissue 
usually change in the same direction in the rat (except in female 
rats after ovariectomy), which suggests that both receptors may 
play similar roles. Third, the expression of GPR55 in adipose tis-
sue and plasma LPI concentrations usually change in the oppo-
site directions (except in obese humans), suggesting that either 
LPI down-regulates the receptor or GPR55 regulates the level 
of its endogenous ligand. Finally, the regulation of LPI-GPR55 
system may be species-specific as evidenced by opposite changes 
in human versus rodent obesity.
role of GPr55 in adipose tissue
In explants of human visceral adipose tissue LPI increased the 
expression of enzymes involved in fatty acid synthesis: acetyl-
CoA carboxylase (ACC) and fatty acid synthase (FAS), as well as 
Table 2. Effect of physiologic and pathologic factors on the expression of GPR55 and CB1 receptors in adipose tissue and plasma 
LPI concentration




Obesity ↑ ↑ ↑ Human ↑ ↑
IGT/T2DM ↑ ↓ ↑ Human
Obesity ↓ ? ↑ Mice (ob/
ob)
↑ 0
High-fat diet-induced obesity ↓ ? ↑ Rat ↑ ↑
short-term fasting ↑ ↓ ↑ Rat ↔ ↓
Chronic food deprivation ↑ ? ↑ Rat ↓ ↓
Late pregnancy ↓ ↑ ↓ Rat ↑ ↑
Orchidectomy ↓ ↑ ↓ Male rats ↑ ↑
Ovariectomy ↑ ↓ ↓ Female rats ↑ ?
Hyperthyroidism ↓ ? ↔ Rats ↓ ?
IGT – impaired glucose tolerance
 T2DM – type 2 diabetes mellitus
↑ - increase
↓ - decrease
↔ - no change
? – not examined
0 – leptin is not produced in ob/ob mice
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of peroxisome proliferator-activated receptor-γ (PPAR-γ) which 
regulates adipocyte differentiation (17). In addition, LPI mark-
edly increased the expression of GPR55, which suggests that 
up-regulation of GPR55 in obese individuals may result from 
the increase in LPI level (17). LPI also tended to increase the ex-
pression of leptin and adiponectin in visceral adipose tissue, but 
these effects were not significant. LPI had no effect on lipogenic 
enzymes, PPAR-γ or adipokines in subcutaneous adipose tissue. 
It induced a rapid increase in intracellular Ca2+ in cultured hu-
man differentiated adipocytes; the effect more marked in cells 
isolated from visceral than from subcutaneous adipose tissue. 
However, LPI had no effect on the differentiation and lipid ac-
cumulation in cultured murine 3T3-L1 adipocytes (17). These 
data further suggest that the role of GPR55 signaling in adi-
pose tissue is species-specific. It should be stressed that LPI has 
GPR55-independent effects in some systems and it is unclear if 
this receptor is involved in all effects of LPI in the adipose tissue. 
In addition to GPR55, LPI may target other G protein-coupled 
receptors such as GPR119 or TRPV1 as well as may modulate 
ion channels in receptor-independent manner (8). LPI used in 
experimental studies may be converted by lysophospholipase D 
to lysophosphatidic acid. Thus, some effects attributed to LPI 
may in fact be mediated by LPA. GPR55 knockout mice exhibit 
no gross abnormalities of body fat content or body weight which 
suggests against the major role of this receptor in adipose tissue, 
at least in rodents. The recent characterization of specific GPR55 
agonists and antagonists may shed more light on the role of this 
receptor.
One may also speculate about other roles of LPI-GPR55 sys-
tem in the adipose tissue. First, GPR55 stimulates angiogenesis 
(19), which is indispensable for adipose tissue expansion in obe-
sity (20). Second, LPI was demonstrated to increase the expres-
sion of adhesion proteins on endothelial cells (21); the process 
crucial for recruitment of monocytes to adipose tissue which is 
observed in obesity. Third, GPR55 is expressed in mast cells and 
endocannabinoids influence the release of nerve growth factor 
(NGF) synthesized and stored in these “master” cells (22; also 
see 23). Further, mast cells are found in the adipose tissue of 
individuals with cardiometabolic diseases, and contribute to tri-
glyceride accumulation, insulin resistance and adipo-inflamma-
tion (24,25).
role of GPr55 in cardiovascular system and insulin 
secretion: implications for the metabolic syndrome
Obesity is a well-known risk factor of cardiovascular diseases 
such as arterial hypertension, atherosclerosis, ischemic heart 
disease and heart failure; all of them being associated with en-
dothelial dysfunction. GPR55 is expressed in endothelial cells 
(26). However, the role of LPI-GPR55 signaling in the regulation 
of vascular tone is controversial. Early studies suggested that 
LPI impairs acetylcholine-induced relaxation of rat mesenteric 
arteries mediated by endothelium-dependent hyperpolarizing 
factor (27). Endothelium-dependent hyperpolarization plays an 
important role in the regulation of vascular tone in small arter-
ies and arterioles which are crucial for the regulation of total 
peripheral resistance and blood pressure. This phenomenon is 
mainly associated with the activation of small- and intermediate-
conductance calcium-activated potassium channels in endothe-
lial cells and their hyperpolarization; hyperpolarization is then 
transferred to vascular smooth muscle cells via myoendothelial 
gap junctions (28). In human umbilical vein-derived endothe-
lial cells, LPI induces a rapid and transient release of intracel-
lular Ca2+ resulting in the activation of large-conductance Ca2+-
activated potassium channels and membrane hyperpolarization, 
followed by sustained depolarization (29). Hyperpolarization is 
augmented by overexpression of GPR55 and inhibited by anti-
GPR55 siRNA, whereas depolarization is not mediated by this 
receptor but results from stimulation by LPI of non-specific 
cation channel and/or inhibition of Na+,K+-ATPase. These data 
suggest that LPI may induce either vasorelaxation or vasocon-
striction.  Other studies in the same cell model demonstrated 
that LPI increases intracellular Ca2+ concentration in endothe-
lial cells and activates large- and intermediate-conductance cal-
cium-activated potassium channels in the GPR55-independent 
manner (30,31). In addition, LPI augmented endothelial hyper-
polarization induced by low but attenuated hyperpolarization 
induced by high histamine concentrations (31). In contrast to 
endothelial cells, LPI enhanced store-operated calcium entry in 
vascular smooth muscle cells and thus to induces their contrac-
tion (32). In the only study in which vascular tone was measured, 
LPI inhibited norepinephrine-induced vasoconstriction in vivo 
(33). Whether elevated LPI concentration in human obesity (17) 
contributes to abnormalities of vascular tone associated with the 
metabolic syndrome or is the compensatory mechanism aimed 
to preserve vasorelaxation remains to be established.
Recently, LPI has been demonstrated to increase intracellular 
Ca2+ concentration in rat neonatal ventricular cardiomyocytes 
in GPR55-dependent manner (34). This effect resulted from ac-
tivation of both calcium influx through sarcolemmal L-type Ca2+ 
channels and release of Ca2+ from the intracellular stores. Inter-
estingly, apart from plasma membrane, GPR55 receptors were 
identified in endolysosomes in these cells, and LPI microinject-
ed into the intracellular space induced, in the GPR55-dependent 
manner, calcium release from this compartment through the 
NAADP-sensitive two-pore calcium channels (34). Functional 
implications of these findings for the heart are not clear, how-
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ever, increase in intracellular Ca2+ in cardiomyocytes induced 
by membrane depolarization mediates not only myocardial con-
traction (excitation-contraction coupling) but also, in the long 
run, changes in gene expression involved in myocardial hyper-
trophy/remodeling (excitation-transcription coupling).
Furthermore, LPI induces adhesion of inflammatory cells 
to the endothelium, although to a lesser extent than lysophos-
phatidylcholine (21), and stimulates migration of smooth 
muscle cells (35); both processes crucial for the development 
of atherosclerosis. As these reports were published before the 
“GPR55 era” in LPI research, they did not attract much at-
tention. Currently more focused studies on this topic are ex-
pected. On the other hand, LPI was recently demonstrated to 
inhibit ADP-induced platelet aggregation; the effect expected 
to be antiatherogenic (36).
In addition, LPI stimulates hypertrophy of renal tubular cells 
and thus may contribute to obesity-associated nephropathy (37); 
the major cause of chronic kidney disease in developed coun-
tries (38). Finally, LPI-GPR55 system is involved in cancer as 
evidenced by the following observations: (i) GPR55 is expressed 
in many cancer cell lines, (ii) synthesis and release of LPI by can-
cer cells is increased, (iii) increase in plasma and ascites fluid 
LPI concentration in patients with ovarian, breast and prostate 
cancer was observed, (iv) oncogenic transformation induced by 
overexpression of K-Ras protein increases LPI synthesis, (v) LPI 
stimulates proliferation,  migration and invasiveness of many 
cancer cells (39). Obesity is associated with increased risk of 
certain cancers but the mechanism of this association is incom-
pletely understood (40).
Two independent studies have demonstrated that GPR55 is 
abundantly expressed in pancreatic β cells at both mRNA and 
protein levels. In addition, natural and synthetic GPR55 agonists 
augment glucose-induced insulin secretion in vitro and in vivo 
(41,42; see 43 for another plasma lipid mediator with pleiotropic 
activities). 
Conclusion and future directions
Data accumulated over the last years indicate that LPI-GPR55 
signaling system is active in many tissues and regulates an ar-
ray of physiological processes. In humans, both circulating LPI 
concentration and the expression of GPR55 in adipose tissue is 
higher in obese than in lean subjects, and greater in patients with 
impaired than with normal glucose tolerance. Although these 
results as well as anabolic effect of LPI in adipose tissue explants 
suggest the role of this system in the pathogenesis of obesity, 
studies performed in experimental animals indicate that its role 
is most likely species specific. In addition, LPI-GPR55 system is 
involved in the regulation of many other processes crucial for 
the pathogenesis of metabolic syndrome and its complications, 
although its role in vascular tone, atherogenesis and myocardial 
function is just started to being examined. Interestingly, whereas 
some effects of GPR55, for example on adipocyte metabolism, 
are detrimental, other ones such as inhibition of platelet aggre-
gation or stimulation of insulin secretion are beneficial. Both 
sequence homology between GPR55 and CB receptors and 
structural similarity and metabolic relationships between their 
ligands suggest that both may be important in adipose tissue bi-
ology. Recently, highly selective GPR55 agonists and antagonists 
were developed (34) which will expectedly facilitate research in 
the field. In broader terms, the existence of CB1- and GPR55-de-
pendent signaling suggest that adipose tissue secretome consists 
of not only proteins (adipokines) but also biologically active lip-
ids (“lipid adipomediators”); possibly not very surprising phe-
nomenon for tissue with the highest lipid content in the body. 
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